NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against International Flavors & Fragrances Inc. (“IFF” or “the Company”) (NYSE:IFF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired IFF securities between May 7, 2018 and August 5, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/iff.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) that Frutarom had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom’s financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 5, 2019, IFF announced its financial results for the second quarter of 2019. IFF significantly lowered its 2019 guidance, advising investors that it expects adjusted earnings per share (“EPS”) of $4.85 to $5.05 on revenue of $5.15 billion to $5.25 billion, down from its previous guidance of adjusted EPS in the range of $4.90 to $5.10 and revenue of $5.2 billion to $5.3 billion. In addition, IFF disclosed that it is investigating improper payments made by two businesses of its Israeli subsidiary Frutarom “operating principally in Russia and Ukraine . . . to representatives of a number of customers.” On this news, IFF’s stock price fell $22.56 per share, or 15.95%, to close at $118.91 per share on August 6, 2019.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/iff. or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss IFF you have until October 11, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557359

NEW YORK, NY / ACCESSWIRE/ August 26, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Omnicell, Inc. (NASDAQGS:OMCL)
Class Period: October 25, 2018 to July 11, 2019
Lead Plaintiff Deadline: September 16, 2019

The complaint alleges that during the class period Omnicell, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in OMCL: http://www.kleinstocklaw.com/pslra-1/omnicell-inc-loss-submission-form?id=3175&from=1

Curaleaf Holdings, Inc. (OTCMKTS:CURLF)
Class Period: November 21, 2018 to July 22, 2019
Lead Plaintiff Deadline: October 4, 2019

Curaleaf Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in CURLF: http://www.kleinstocklaw.com/pslra-1/curaleaf-holdings-inc-loss-submission-form?id=3175&from=1

Evolent Health, Inc. (NYSE:EVH)
Class Period: March 3, 2017 to May 28, 2019
Lead Plaintiff Deadline: October 7, 2019

According to the complaint, Evolent Health, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Evolent’s partnership model was not aligned with its partners, as it was designed to parasitically increase its own revenue by extracting enormous administrative and management fees at the expense of its partners such as Passport Health Plan (“Passport”); (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees, and money to such an extent that Passport was left on the verge of insolvency; (4) for several months, Passport was conducting a bidding process to sell itself to a financial buyer to prevent liquidation; and (5) as a result of the foregoing, Defendants public statements were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EVH: http://www.kleinstocklaw.com/pslra-1/evolent-health-inc-loss-submission-form?id=3175&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 557432

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Karyopharm Therapeutics Inc (NASDAQGS:KPTI)
Class Period: on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.
Lead Plaintiff Deadline: September 23, 2019

Karyopharm Therapeutics Inc allegedly made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Learn about your recoverable losses in KPTI: http://www.kleinstocklaw.com/pslra-1/karyopharm-therapeutics-inc-loss-submission-form?id=3174&from=1

Carbonite, Inc. (NASDAQGM:CARB)
Class Period: February 7, 2019 to July 25, 2019
Lead Plaintiff Deadline: September 30, 2019

The complaint alleges Carbonite, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Carbonite’s Server Backup VM Edition was of poor quality and technologically flawed; (ii) Carbonite was receiving poor reviews and complaints from customers about the Server Backup VM Edition; (iii) the poor quality and technological flaws of the Server Backup VM Edition was acting as a “disruptive” factor throughout the Carbonite salesforce and keeping that sales organization from closing opportunistically on several larger deals during fiscal 2019; and (iv) as a result of the foregoing, Carbonite lacked any reasonable basis for issuing its positive projections and financial forecasts.

Learn about your recoverable losses in CARB: http://www.kleinstocklaw.com/pslra-1/carbonite-inc-loss-submission-form?id=3174&from=1

Pluralsight, Inc. (NASDAQGS:PS)
Class Period: August 2, 2018 to July 31, 2019
Lead Plaintiff Deadline: October 15, 2019

According to the filed complaint, the Company failed to disclose that Pluralsight was experiencing substantial delays in hiring and properly training the salesforce necessary to meet its lofty billing projections. In addition, the Company knew at the time of the March 2019 secondary public offering (“SPO”) that it was behind schedule onboarding new sales representatives, which was hurting the Company’s sales execution and preventing Pluralsight from meeting its high growth projections. Instead of disclosing such facts at the time of the SPO, and to cash-out at inflated prices, Defendants intentionally obscured and omitted this pertinent information from investors.

Learn about your recoverable losses in PS: http://www.kleinstocklaw.com/pslra-1/pluralsight-inc-loss-submission-form?id=3174&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 557431

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Just Energy Group Inc. (NYSE:JE)

Lawsuit on behalf of: investors who purchased November 9, 2017 – July 23, 2019
Lead Plaintiff Deadline : September 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/just-energy-group-inc-loss-form?prid=3173&wire=1

According to the filed complaint, during the class period, Just Energy Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company experienced customer enrollment and nonpayment issues; (2) as a result, the Company was reasonably likely to incur an impairment charge to its accounts receivable; (3) as a result, the Company lacked adequate internal control over its financial reporting; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Cardinal Health, Inc. (NYSE:CAH)

Lawsuit on behalf of: investors who purchased March 2, 2015 – May 2, 2018
Lead Plaintiff Deadline : September 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cardinal-health-inc-loss-form?prid=3173&wire=1

According to the filed complaint, during the class period, Cardinal Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) following Cardinal’s acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis’s performance were never implemented across Cordis; 2) Cordis’s antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis’s inventory balances; 5) Cordis was not “performing well” and its integration was not “on track,” “going incredibly well” or “largely on plan”; and 6) to correct Cordis’s deficiencies, the Company would have to make substantial investments in Cordis’s IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.

International Flavors & Fragrances Inc. (NYSE:IFF)

Lawsuit on behalf of: investors who purchased May 7, 2018 – August 5, 2019
Lead Plaintiff Deadline : October 11, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/international-flavors-fragrances-inc-loss-form?prid=3173&wire=1

According to the filed complaint, during the class period, International Flavors & Fragrances Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that Frutarom Industries Ltd. (“Frutarom”), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom’s financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 557430

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Intelligent Systems Corporation (NYSE:INS)

Lawsuit on behalf of: investors who purchased January 23, 2019 – May 29, 2019
Lead Plaintiff Deadline : September 9, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intelligent-systems-corporation-loss-form?prid=3172&wire=1

According to the filed complaint, during the class period, Intelligent Systems Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) Defendant Petit, the “financial expert” on the Company’s Audit Committee, engaged in accounting fraud as the CEO of MiMedx Group; (2) the Company’s CEO, Defendant Strange, engaged in undisclosed related-party transactions with Defendant Petit and others and had an undisclosed personal relationship with the Company’s auditor; (3) the Company had its employees set up or take control of shell companies in Asia so they could partake in undisclosed related-party transactions for the purpose of either fabricating revenue for the Company and/or siphoning money out of the Company; and (4) as a result, Defendants’ statements about Intelligent Systems’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

CannTrust Holdings Inc. (NYSE:CTST)

Lawsuit on behalf of: investors who purchased November 14, 2018 – July 12, 2019
Lead Plaintiff Deadline : September 9, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/canntrust-holdings-inc-loss-form?prid=3172&wire=1

According to filed complaints, CannTrust Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Mallinckrodt Public Limited Company (NYSE:MNK)

Lawsuit on behalf of: investors who purchased February 28, 2018 – July 16, 2019
Lead Plaintiff Deadline : September 24, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mallinckrodt-public-limited-company-loss-form?prid=3172&wire=1

According to the filed complaint, during the class period, Mallinckrodt Public Limited Company made materially false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 557429

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FedEx Corporation (“FedEx” or the “Company”) (NYSE:FDX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired FedEx securities from September 19, 2017 through December 18, 2018,inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fdx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

FedEx is a global logistics company that ships goods to commercial and residential customers throughout the world.

In July 2016, FedEx significantly expanded its international operations through its $4.8 billion acquisition of TNT Express N.V. (“TNT”), a Netherlands-based logistics company with operations concentrated in Europe. To date, this has been the largest acquisition in FedEx history. This acquisition instantly added billions of dollars of European revenues to FedEx’s top line and increased the Company’s international revenue mix from 24% in fiscal year 2016 to 33% in fiscal year 2017.

After the acquisition closed, FedEx embarked on an aggressive strategy to integrate it’s legacy European operations with TNT. On March 31, 2017, nine months after completing the acquisition, FedEx issued a three-year operating income improvement target for investors to gauge and track the purported benefits of the TNT acquisition and FedEx’s integration efforts. Specifically, the Company stated that, in fiscal year 2020, its integration with TNT would result in a $1.2 billion to $1.5 billion operating income improvement above its fiscal year 2017 reported operating income (the “TNT Income Improvement Target”).

On June 27, 2017, however, TNT’s operations were crippled by a cyber attack known as NotPetya, which involved the spread of a malware virus throughout TNT’s systems (the “Cyberattack”). NotPetya is considered one of the largest cyber attacks in history, having affected a multitude of companies on a global scale. The timing of the attack was particularly problematic for FedEx, as TNT’s systems were paralyzed during the critical period involving the integration of TNT with the Company’s legacy European operations.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) TNT’s overall package volume growth was slowing as TNT’s large customers permanently took their business to competitors after the Cyberattack; (ii) as a result of the customer attrition, TNT was experiencing an increased shift in product mix from higher-margin parcel services to lower-margin freight services; (iii) the anticipated costs and timeframe to integrate and restore the TNT network were significantly larger and longer than disclosed; (iv) FedEx was not on track to achieve the TNT Income Improvement Target; and (v) as a result of these undisclosed negative trends and cost issues, FedEx’s positive statements about TNT’s recovery from the Cyberattack, integration into FedEx’s legacy operations, customer mix, customer service levels, profitability, and prospects lacked a reasonable basis.

The Class Period starts on September 19, 2017, when FedEx reported that the Cyberattack had negatively impacted its first quarter 2018 results (ended August 30, 2017). During the related earnings call, however, Defendants assured investors that all critical TNT systems were fully restored and fixes to its customer-specific systems were expected to be finalized by the end of September 2017. Company executives also reaffirmed the TNT Income Improvement Target. Analysts maintained their ratings and price targets on FedEx stock due to the Company’s assurances about its recovery from the Cyberattack. On this news, FedEx stock increased $4.50 per share, or roughly 2.1%, to close at $220.50 per share on September 20, 2017.

The truth about TNT’s deteriorating business was revealed through a series of disclosures. While making these disclosures, however, Defendants continued to assure investors that FedEx would still meet the TNT Income Improvement Target and that TNT had successfully recovered in the wake of the Cyberattack.

On June 19, 2018, FedEx provided a disappointing capital expenditure outlook for its FedEx Express segment, the reporting segment that includes TNT’s results, and reported higher-than-expected TNT integration expenses. On this news, FedEx shares dropped $6.96 per share, or 2.69%, to close at $251.43 per share on June 20, 2018. Despite these issues, Defendants assured investors that the Company was “on track” to meet the TNT Income Improvement Target and that TNT’s year-over-year growth had resumed.

On September 17, 2018, FedEx reported lower-than-expected earnings for its first quarter ended August 30, 2018. The Company partially attributed these results to higher-than-expected TNT integration costs. On this news, FedEx stock dropped $14.15 per share, or 5.5%, to close at $241.58 per share on September 18, 2018. Defendants, however, again assured investors that the Company was on track to meet the TNT Income Improvement Target, and touted that the Company’s “strong international volume growth reflect[ed] [FedEx’s] recovery from the TNT cyberattack.”

On December 7, 2018, FedEx announced that David L. Cunningham would retire as FedEx Express’ President and Chief Executive Officer (“CEO”) on December 31, 2018. Analysts immediately suggested that Cunningham’s “retirement” was a result of performance issues within the Company’s FedEx Express segment. On this news, FedEx stock dropped $13.67 per share, or roughly 6.4%, to close at $201.39 per share on December 7, 2018.

The full extent of TNT’s deteriorating business was revealed to investors on December 18, 2018, after the close of trading. On that date, FedEx reported a large profit miss for its second fiscal quarter ended November 30, 2018. Defendants attributed the disappointing results to lower package volumes in Europe and a negative shift in TNT’s product mix to lower margin freight business following the Cyberattack, which had occurred well over a year ago. The Company also lowered its fiscal 2019 earnings guidance and announced that the TNT Income Improvement Target would no longer be achievable by fiscal year 2020. On this news, FedEx stock dropped $22.50 per share, or roughly 12.2%, to close at $162.51 per share on December 19, 2018.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/fdx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in FedEx you have until August 26, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 556474

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Ideanomics Inc. (NASDAQ:IDEX)
Class Period: May 15, 2017 – November 13, 2018,
Deadline: September 17, 2019
For more info: www.bgandg.com/idex

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) costs associated with building out Ideanomics’ U.S. infrastructure and hiring its new executive team were negatively impacting the Company’s bottom line performance; (2) as a result, Ideanomics was highly unlikely to meet its 2018 EBITDA guidance; (3) Ideanomics’ margins in its oil trading and consumer electronics businesses were too low for those businesses to remain viable; and (4) as a result, Ideanomics’ public statements were materially false and misleading at all relevant times.

Netflix, Inc. (NASDAQ:NFLX)
Class Period: April 17, 2019 – July 17, 2019
Deadline: September 20, 2019
For more info: www.bgandg.com/nflx

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557353

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Verb Technology Company, Inc. (NASDAQ:VERB)
Class Period: January 3, 2018 – May 2, 2018
Deadline: September 9, 2019
For more info: www.bgandg.com/verb

The complaint alleges that on January 3, 2018, Verb revealed a purported agreement with Oracle America, Inc. (the “Oracle Agreement”) and filed Form 8-K with the United States Securities and Exchange Commission omitting the text of the agreement itself. The complaint continues to allege that throughout the Class Period, Verb continued to hype this relationship. During this time, Verb stock price increased over 200% up from $0.12 per share on January 3, 2018 to $2.70 on April 19, 2018.

Reckitt Benckiser Group plc (OTCMKT:RBGLY)
Class Period: July 28, 2014 – April 9, 2019
Deadline: September 16, 2019
For more info: www.bgandg.com/rbgly

The complaint alleges that before and throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material adverse information. The complaint alleges that Reckitt was involved in a scheme that generated over $3 billion in proceeds enabling opiate abuse among U.S. consumers and mislead investors and the public concerning the health and safety risks of Suboxone Film, its new key opiate product. Specifically, the complaint alleges that Reckitt senior executives planned to switch prescribers from Suboxone Tablets to its Suboxone Film, which had similar active ingredients to Suboxone Tablets, but is dispensed by a thin film placed under the tongue and stored in single-use foil wrappings. In order to prevent generic competition, the company created a marketing campaign to hype the purported safety benefits of Suboxone Film over Suboxone Tablets. The complaint continues to allege that the campaign was fabricating safety concerns of existing treatments, hoping to delay the entry and approval of generics for Suboxone Tablets. As a result, the sales of Suboxone Film grew. From 2010 and 2014, Reckitt revenues from sales of the drug rose to over $840 million annually. As a result of defendants’ false and misleading statements and/or omissions regarding the alleged scheme, Reckitt ADSs traded at artificially inflated prices.

Omnicell, Inc. (NASDAQ:OMCL)
Class Period: October 25, 2018 – July 11, 2019
Deadline: September 16, 2019
For more info: www.bgandg.com/omcl

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Omnicell recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) consequently, the Company would be required to write-off certain inventory; (5) Omnicell misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557338

Eligible Shareholders will Receive Five Shares of Taronis Fuels Initial Listing Price Set at $1.00 Per Share

PHOENIX, AZ / ACCESSWIRE / August 26, 2019 / Taronis Technologies, Inc., (“Taronis Technologies” or “the Company”) (NASDAQ:TRNX), a leading clean technology company in the renewable resources and environmental conservation industry, today announced that the Board of Directors of Taronis Technologies has approved an increased stock dividend ratio of 5:1, which is an increase from the previous 1:1 ratio. This means that Taronis Technologies will distribute five shares of Taronis Fuels, Inc. (“Taronis Fuels”) common stock for every one share of Taronis Technologies common stock outstanding on the record date for the share distribution. The new record date for the share distribution is anticipated to be November 5, 2019, which is 60 days from the date the Company plans to file the Taronis Fuels Form 10 registration statement.

It is important to note that during the period from the record date to the distribution date, shares of Taronis Technologies will be trading “with dividend” in the “regular-way” market, which means that any seller, including short sellers, of shares of Taronis Technologies common stock will be liable to the buyer of these shares for the full amount of the stock distribution of the Taronis Fuels common stock related to such shares.

The Board of Directors elected to increase the dividend ratio to offset the effects of the Taronis Technologies reverse stock split for the benefit of existing shareholders. Nasdaq also required that the value of the upcoming stock dividend be declared in advance. Based on the Company’s current estimates of the value of Taronis Fuels, an initial dividend value of $1.00 per share has been submitted to Nasdaq.

“Our leadership team has consistently advocated for our shareholders, and we have and will continue to diligently pursue objectives to provide maximum shareholder value,” commented Scott Mahoney, CEO of Taronis Technologies. “The upcoming spin-off of Taronis Fuels is intended to provide the maximum possible additional shareholder value. By increasing the Taronis Fuels dividend ratio, we are intentionally undoing the unexpected effects of our recent reverse split of Taronis Technologies on the previous stock dividend ratio.”

“We are also in a unique position where the declared value of the stock dividend now gives shareholders greater clarity on the potential value of Taronis Fuels. We are confident that our anticipated near term milestones for our Amsterdam, El Salvador and Turkey MagneGas projects could further validate this valuation,” concluded Scott Mahoney.

About Taronis Technologies, Inc.

Taronis Technologies, Inc. (TRNX) owns a patented plasma arc technology that enables two primary end use applications for fuel generation and water decontamination.

The Company’s fuel technology enables a wide use of hydrocarbon feedstocks to be readily converted to fossil fuel substitutes. The Company is developing a wide range of end market uses for these fuels, including replacement products for propane, compressed natural gas and liquid natural gas. The Company currently markets a proprietary metal cutting fuel that is highly competitive with acetylene. The Company distributes its proprietary metal cutting fuel through Independent Distributors in the U.S. and through its wholly owned distributors doing business as “MagneGas Welding Supply.” The Company operates 22 locations across California, Texas, Louisiana, and Florida.

The Company’s technology can also be implemented for the decontamination of waste water, including sterilizing water, eradicating all pathogens. The technology is being tested to determine if it can completely eliminate pharmaceutical contaminants such as antibiotics, hormones and other soluble drugs suspended in contaminated water. The technology process is capable of reducing or eliminating other contaminants, such as harmful metals, as well as nitrogen, phosphorus, and potassium levels that trigger toxic algae blooms. The technology has prospective commercial applications in the agricultural, pharmaceutical, and municipal waste markets. For more information on Taronis, please visit the Company’s website at http://www.TaronisTech.com.

Taronis also owns a controlling interest in Water Pilot, LLC. The WATER PILOT® System immediately reduces water consumption and provides live remote consumption monitoring for long term leak protection and water asset management. An integral, client-based alarm and notification system reports to any mobile device. Water Pilot may be appropriate for a wide range of businesses or properties with a water meter. For more information, please visit our website at www.gowaterpilot.com/

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

Investor Contacts:
Michael Khorassani
IR@TaronisTech.com

SOURCE: Taronis Technologies

ReleaseID: 557246